TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T01936 XX ID T01936 XX DT 05.11.1996 (created); ewi. DT 14.10.2014 (updated); yre. CO Copyright (C), QIAGEN. XX FA IKappaB XX SY I-kappaB; IkappaB; Inhibitor kappa B. XX OS mouse, Mus musculus OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; rodentia; myomorpha; muridae; murinae XX FF binds to the RelA (p65) subunit of NF-kappaB [2]; FF has to be phosphorylated before dissociation from NF-kappaB [4]; FF activation may indirectly involve PKC, PKA, haem-regulated eIF-2 kinase (HIF) [4]; FF constant low concentration of NF-kappaB in non-B cells due to low-level turnover of IKappaB [9]; XX IN T00595 RelA-p65; mouse, Mus musculus. XX DR TRANSPATH: MO000026038. XX RN [1]; RE0000090. RX PUBMED: 3129195. RA Baeuerle P. A., Baltimore D. RT Activation of DNA-Binding Activity in an Apparently Cytoplasmic Precursor of the NF-kB Transcription Factor RL Cell 53:211-217 (1988). RN [2]; RE0000609. RX PUBMED: 2691328. RA Baeuerle P., Baltimore D. RT A 65-kD subunit of active NF-kappaB is required for inhibition of NF-kappaB by IkappaB RL Genes Dev. 3:1689-1698 (1989). RN [3]; RE0000627. RX PUBMED: 2612907. RA Roux E., Strubin M., Hagenbuechle O., Wellauer P. K. RT The cell-specific transcription factor PTF1 contains two different subunits that interact with the DNA RL Genes Dev. 3:1613-1624 (1989). RN [4]; RE0001807. RX PUBMED: 2157987. RA Ghosh S., Baltimore D. RT Activation in vitro of NF-kappaB by phosphorylation of its inhibitor IkappaB RL Nature 344:678-682 (1990). RN [5]; RE0002610. RX PUBMED: 3140380. RA Baeuerle P., Baltimore D. RT IkappaB: A specific inhibitor of the NF-kappaB transcription factor RL Science 242:540-546 (1988). RN [6]; RE0004491. RX PUBMED: 8164680. RA Miyamoto S., Chiao P. J., Verma I. M. RT Enhanced IkappaBalpha degradation is responsible for constitutive NF-kappaB activity in mature murine B-cell lines RL Mol. Cell. Biol. 14:3276-3282 (1994). RN [7]; RE0004591. RX PUBMED: 8497253. RA Beg A. A., Finco T. S., Nantermet P. V., Baldwin jr A. S. RT Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IkappaBalpha: a mechanism for NF-kappaB activation RL Mol. Cell. Biol. 13:3301-3310 (1993). RN [8]; RE0004592. RX PUBMED: 8278379. RA Chiao P. J., Miyamoto S., Verma I. M. RT Autoregulation of IkappaBalpha activity RL Proc. Natl. Acad. Sci. USA 91:28-32 (1994). RN [9]; RE0004609. RX PUBMED: 8223478. RA Rice N. R., Ernst M. K. RT In vivo control of NF-kappaB activation by IkappaBalpha RL EMBO J. 12:4685-4695 (1993). RN [10]; RE0004639. RX PUBMED: 7569976. RA Auphan N., Didonato J. A., Rosette C., Helmberg A., Karin M. RT Imunosuppression by glucocorticoids: Inhibition of NF-6B activity through induction of I6B synthesis RL Science 270:286-290 (1995). RN [11]; RE0052767. RX PUBMED: 17161867. RA Kubo-Murai M., Hazeki K., Sukenobu N., Yoshikawa K., Nigorikawa K., Inoue K., Yamamoto T., Matsumoto M., Seya T., Inoue N., Hazeki O. RT Protein kinase Cdelta binds TIRAP/Mal to participate in TLR signaling. RL Mol. Immunol. 44:2257-2264 (2007). RN [12]; RE0054741. RX PUBMED: 17562858. RA Abbott D. W., Yang Y., Hutti J. E., Madhavarapu S., Kelliher M. A., Cantley L. C. RT Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. RL Mol. Cell. Biol. 27:6012-6025 (2007). RN [13]; RE0054797. RX PUBMED: 16484229. RA Zhao J., Kong H. J., Li H., Huang B., Yang M., Zhu C., Bogunovic M., Zheng F., Mayer L., Ozato K., Unkeless J., Xiong H. RT IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. RL J. Biol. Chem. 281:10073-10080 (2006). RN [14]; RE0055294. RX PUBMED: 18719121. RA Chen N. J., Chio I. I., Lin W. J., Duncan G., Chau H., Katz D., Huang H. L., Pike K. A., Hao Z., Su Y. W., Yamamoto K., de Pooter R. F., Zuniga-Pflucker J. C., Wakeham A., Yeh W. C., Mak T. W. RT Beyond tumor necrosis factor receptor: TRADD signaling in toll-like receptors. RL Proc. Natl. Acad. Sci. USA 105:12429-12434 (2008). RN [15]; RE0064839. RX PUBMED: 17277779. RA Qian Y., Liu C., Hartupee J., Altuntas C. Z., Gulen M. F., Jane-Wit D., Xiao J., Lu Y., Giltiay N., Liu J., Kordula T., Zhang Q. W., Vallance B., Swaidani S., Aronica M., Tuohy V. K., Hamilton T., Li X. RT The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. RL Nat. Immunol. 8:247-256 (2007). RN [16]; RE0065746. RX PUBMED: 16809760. RA de la Fuente M. A., Kumar L., Lu B., Geha R. S. RT 3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation. RL Mol. Cell. Biol. 26:5214-5225 (2006). RN [17]; RE0069704. RX PUBMED: 19955178. RA Broglie P., Matsumoto K., Akira S., Brautigan D. L., Ninomiya-Tsuji J. RT Transforming growth factor beta-activated kinase 1 (TAK1) kinase adaptor, TAK1-binding protein 2, plays dual roles in TAK1 signaling by recruiting both an activator and an inhibitor of TAK1 kinase in tumor necrosis factor signaling pathway. RL J. Biol. Chem. 285:2333-2339 (2010). RN [18]; RE0069719. RX PUBMED: 18829460. RA Inagaki M., Omori E., Kim J. Y., Komatsu Y., Scott G., Ray M. K., Yamada G., Matsumoto K., Mishina Y., Ninomiya-Tsuji J. RT TAK1-binding protein 1, TAB1, mediates osmotic stress-induced TAK1 activation but is dispensable for TAK1-mediated cytokine signaling. RL J. Biol. Chem. 283:33080-33086 (2008). RN [19]; RE0070715. RX PUBMED: 21068407. RA Kim K., Kim J. H., Youn B. U., Jin H. M., Kim N. RT Pim-1 regulates RANKL-induced osteoclastogenesis via NF-kappaB activation and NFATc1 induction. RL J. Immunol. 185:7460-7466 (2010). XX //